Dandi Biosciences Acquires Global Rights to Alzheimer's Treatment Development Compound

[Asia Economy Reporter Hyunseok Yoo] Dandi Bioscience, a KONEX-listed company, has secured global rights to a peptide-based Alzheimer's treatment and has officially begun developing a treatment for Alzheimer's dementia, a disease known to be difficult to cure.

On the 23rd, Dandi Bioscience announced through a public disclosure that it signed a technology transfer agreement with the Industry-Academic Cooperation Foundation of Konyang University and three other universities (Konkuk University, Chosun University, Korea University), which had jointly conducted research on the Alzheimer's dementia prevention and treatment substance ‘DD-A279’. The total contract amount is approximately 640 million KRW, with an upfront payment made after the contract and the remaining payments to be made sequentially according to the progress of clinical trials.

Through this contract, Dandi Bioscience acquired exclusive patent rights and global rights, and will commence full-scale development of an Alzheimer's dementia treatment. The company plans to complete preclinical trials this year and enter global Phase 1 clinical trials in 2023.

Alzheimer's disease is known to be caused by the aggregation of amyloid beta (Aβ) in the patient's brain or a rapid increase in neurofibrillary tangles due to the accumulation of hyperphosphorylated tau protein. Currently, many research institutions and global pharmaceutical companies worldwide are challenging the development of dementia treatments, but since the criteria for determining treatment methods are unclear and the factors causing the disease are very diverse, it is difficult to expect fundamental therapeutic effects through single mechanism target treatments or treatments after symptom confirmation. The company explains that this is why the development of treatments that can simultaneously target multiple factors early in the onset, along with preventive measures, is urgently needed.

Park Young-min, CEO of Dandi Bioscience, said, “‘DD-A279’ is a peptide-based new drug substance that effectively inhibits the causative agents of Alzheimer's dementia, has excellent efficacy, and superior price competitiveness compared to competing drugs. Through the proprietary technology secured this time, we will develop a Best-in-Class innovative new drug that overcomes the limitations of existing single-target drugs and bring hope to patients and families suffering from dementia.”

This content was produced with the assistance of AI translation services.